Skip to main content

Advertisement

SpringerLink
Log in

Molecular imaging of hypoxia in non-small-cell lung cancer

  • Review Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Non-small-cell lung cancer (NSCLC) is the commonest cancer worldwide but survival remains poor with a high risk of relapse, particularly after nonsurgical treatment. Hypoxia is present in a variety of solid tumours, including NSCLC. It is associated with treatment resistance and a poor prognosis, although when recognised may be amenable to different treatment strategies. Thus, noninvasive assessment of intratumoral hypoxia could be used to stratify patients for modification of subsequent treatment to improve tumour control. Molecular imaging approaches targeting hypoxic cells have shown some early success in the clinical setting. This review evaluates the evidence for hypoxia imaging using PET in NSCLC and explores its potential clinical utility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

    Article  CAS  PubMed  Google Scholar 

  2. Cancer Research UK. Lung cancer incidence statistics. Available at http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/incidence/. Accessed 7 Feb 2015.

  3. Cancer Research UK. Lung cancer survival statistics. Available at http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/. Accessed 7 Feb 2015.

  4. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–76.

    Article  CAS  PubMed  Google Scholar 

  5. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225–39.

    Article  CAS  PubMed  Google Scholar 

  6. Hockel M, Vorndran B, Schlenger K, Baussmann E, Knapstein PG. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol. 1993;51:141–9.

    Article  CAS  PubMed  Google Scholar 

  7. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31–9.

    Article  CAS  PubMed  Google Scholar 

  8. Wilhelm R, Kovacs G, Heinrichsohn D, Galalae R, Kimmig B. Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin level. Strahlenther Onkol. 1998;174:128–32.

    Article  CAS  PubMed  Google Scholar 

  9. Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med. 2011;15:1239–53.

    Article  CAS  PubMed  Google Scholar 

  10. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12:1507–14.

    Article  CAS  PubMed  Google Scholar 

  11. Horsman MR, Wouters BG, Joiner MC, Overgaard J. The oxygen effect and fractionated radiotherapy. In: Joiner M, van der Kogel A, editors. Basic clinical radiobiology. 4th ed. London: Hodder Arnold; 2009. p. 207–16.

    Chapter  Google Scholar 

  12. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638–48.

    Article  CAS  PubMed  Google Scholar 

  13. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14:430–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25:4066–74.

    Article  PubMed  Google Scholar 

  15. Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev. 2012;4:CD005007.

  16. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – a systematic review and meta-analysis. Radiother Oncol. 2011;100:22–32.

    Article  PubMed  Google Scholar 

  17. Langenbacher M, Abdel-Jalil RJ, Voelter W, Weinmann M, Huber SM. In vitro hypoxic cytotoxicity and hypoxic radiosensitization. Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine. Strahlenther Onkol. 2013;189:246–54.

    Article  CAS  PubMed  Google Scholar 

  18. Beck R, Roper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973–80.

    Article  CAS  PubMed  Google Scholar 

  19. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012;30:1777–83.

    Article  CAS  PubMed  Google Scholar 

  20. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010;28:4912–8.

    Article  PubMed  Google Scholar 

  21. Toma-Dasu I, Uhrdin J, Antonovic L, Dasu A, Nuyts S, Dirix P, et al. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol. 2012;51:222–30.

    Article  PubMed  Google Scholar 

  22. Henriques de Figueiredo B, Zacharatou C, Galland-Girodet S, Benech J, De Clermont-Gallerande H, Lamare F, et al. Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers. Strahlenther Onkol. 2014. doi:10.1007/s00066-014-0752-8.

    PubMed  Google Scholar 

  23. Chia K, Fleming IN, Blower PJ. Hypoxia imaging with PET: which tracers and why? Nucl Med Commun. 2012;33:217–22.

    Article  PubMed  Google Scholar 

  24. Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol. 1991;42:2387–95.

    Article  CAS  PubMed  Google Scholar 

  25. Walton MI, Workman P. Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol. 1987;36:887–96.

    Article  CAS  PubMed  Google Scholar 

  26. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 1983;43:1523–8.

    CAS  PubMed  Google Scholar 

  27. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med. 2007;37:451–61.

    Article  PubMed  Google Scholar 

  28. Michalski MH, Chen X. Molecular imaging in cancer treatment. Eur J Nucl Med Mol Imaging. 2011;38:358–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Saunders ME, Dische S, Anderson P, Flockhart IR. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum. Br J Cancer Suppl. 1978;3:268–70.

    PubMed Central  CAS  PubMed  Google Scholar 

  30. Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA, et al. A comparative study of the hypoxia PET tracers [(18)F]HX4, [(18)F]FAZA, and [(18)F]FMISO in a preclinical tumor model. Int J Radiat Oncol Biol Phys. 2015;91:351–9. doi:10.1016/j.ijrobp.2014.09.045.

    Article  CAS  PubMed  Google Scholar 

  31. Bentzen L, Keiding S, Horsman MR, Gronroos T, Hansen SB, Overgaard J. Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol. 2002;41:304–12.

    Article  CAS  PubMed  Google Scholar 

  32. Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, Vermaelen P, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer. 2004;91:1947–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, et al. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol. 2006;80:157–64.

    Article  CAS  PubMed  Google Scholar 

  34. Bentzen L, Keiding S, Nordsmark M, Falborg L, Hansen SB, Keller J, et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol. 2003;67:339–44.

    Article  CAS  PubMed  Google Scholar 

  35. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer. 2007;7:113.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P, et al. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol. 2004;180:616–22.

    Article  PubMed  Google Scholar 

  37. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, et al. FDG – a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging. 2006;33:1426–31.

    Article  CAS  PubMed  Google Scholar 

  38. Mortensen LS, Buus S, Nordsmark M, Bentzen L, Munk OL, Keiding S, et al. Identifying hypoxia in human tumors: a correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol. 2010;49:934–40.

    Article  CAS  PubMed  Google Scholar 

  39. Chang J, Wen B, Kazanzides P, Zanzonico P, Finn RD, Fichtinger G, et al. A robotic system for 18F-FMISO PET-guided intratumoral pO2 measurements. Med Phys. 2009;36:5301–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts SA. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med. 2014;55:515–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391–8.

    Article  CAS  PubMed  Google Scholar 

  42. Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199–212.

    Article  CAS  PubMed  Google Scholar 

  43. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417–28.

    Article  CAS  PubMed  Google Scholar 

  44. Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–60.

    PubMed  Google Scholar 

  46. Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med. 2006;47:1921–6.

    CAS  PubMed  Google Scholar 

  47. Chia K, Weeks AJ, Paul RL, Cleij M, Mullen G, Blower PJ. Can PET hypoxia tracers predict radioresistance? Nucl Med Biol. 2010;37:725.

    Article  Google Scholar 

  48. Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I, et al. Simultaneous positron emission tomography (PET) assessment of metabolism with (18)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (18)F-fluoro-thymidine (FLT), and hypoxia with (18)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol. 2011;98:109–16.

    Article  CAS  PubMed  Google Scholar 

  49. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990;122:301–8.

    Article  CAS  PubMed  Google Scholar 

  50. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003;30:317–26.

    Article  CAS  PubMed  Google Scholar 

  51. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106–13.

    PubMed  Google Scholar 

  52. Busk M, Horsman MR, Jakobsen S, Keiding S, van der Kogel AJ, Bussink J, et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys. 2008;70:1202–12.

    Article  CAS  PubMed  Google Scholar 

  53. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging. 2013;40:186–97.

    Article  CAS  PubMed  Google Scholar 

  54. Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA – first small animal PET results. J Pharm Pharm Sci. 2007;10:203–11.

    CAS  PubMed  Google Scholar 

  55. Maier FC, Kneilling M, Reischl G, Cay F, Bukala D, Schmid A, et al. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [18F]-fluoro-azomycinarabino-furanoside ([(1)(8)F]FAZA). Radiat Oncol. 2011;6:165.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, et al. Initial results of hypoxia imaging using 1-α-D-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging. 2009;36:1565–73.

    Article  CAS  PubMed  Google Scholar 

  57. Bollineni VR, Kerner GS, Pruim J, Steenbakkers RJ, Wiegman EM, Koole MJ, et al. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. J Nucl Med. 2013;54:1175–80.

    Article  CAS  PubMed  Google Scholar 

  58. Trinkaus ME, Blum R, Rischin D, Callahan J, Bressel M, Segard T, et al. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. J Med Imaging Radiat Oncol. 2013;57:475–81.

    Article  PubMed  Google Scholar 

  59. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194:795–800.

    Article  CAS  PubMed  Google Scholar 

  60. Gronroos T, Eskola O, Lehtio K, Minn H, Marjamaki P, Bergman J, et al. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med. 2001;42:1397–404.

    CAS  PubMed  Google Scholar 

  61. Gronroos T, Bentzen L, Marjamaki P, Murata R, Horsman MR, Keiding S, et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:513–20.

    Article  PubMed  Google Scholar 

  62. Hu M, Xing L, Mu D, Yang W, Yang G, Kong L, et al. Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer. Clin Nucl Med. 2013;38:591–6.

    Article  PubMed  Google Scholar 

  63. Li L, Hu M, Zhu H, Zhao W, Yang G, Yu J. Comparison of 18F-fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11:335–40.

    Article  PubMed  Google Scholar 

  64. Doss M, Zhang JJ, Belanger MJ, Stubbs JB, Hostetler ED, Alpaugh K, et al. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun. 2010;31:1016–24.

    PubMed Central  CAS  PubMed  Google Scholar 

  65. Dubois LJ, Lieuwes NG, Janssen MH, Peeters WJ, Windhorst AD, Walsh JC, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A. 2011;108:14620–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging. 2010;37:1663–8.

    Article  PubMed  Google Scholar 

  67. Zegers CM, van Elmpt W, Wierts R, Reymen B, Sharifi H, Ollers MC, et al. Hypoxia imaging with [18F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol. 2013;109:58–64.

    Article  PubMed  Google Scholar 

  68. Zegers CM, van Elmpt W, Reymen B, Even AJ, Troost EG, Ollers MC, et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Cancer Res. 2014;20:6389–97. doi:10.1158/1078-0432.CCR-14-1524.

    Article  CAS  PubMed  Google Scholar 

  69. Kaneta T, Takai Y, Iwata R, Hakamatsuka T, Yasuda H, Nakayama K, et al. Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl Med. 2007;21:101–7.

    Article  CAS  PubMed  Google Scholar 

  70. Laughlin KM, Evans SM, Jenkins WT, Tracy M, Chan CY, Lord EM, et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther. 1996;277:1049–57.

    CAS  PubMed  Google Scholar 

  71. Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, et al. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. J Nucl Med. 2013;54:1339–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–60.

    CAS  PubMed  Google Scholar 

  73. Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499–504.

    Article  CAS  PubMed  Google Scholar 

  74. Holland JP, Barnard PJ, Collison D, Dilworth JR, Edge R, Green JC, et al. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chemistry. 2008;14:5890–907.

    Article  CAS  PubMed  Google Scholar 

  75. Dearling JL, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol. 2010;37:237–43.

    Article  CAS  PubMed  Google Scholar 

  76. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45:1420–31.

    Article  CAS  PubMed  Google Scholar 

  77. Bourgeois M, Rajerison H, Guerard F, Mougin-Degraef M, Barbet J, Michel N, et al. Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO – a selected review. Nucl Med Rev Cent East Eur. 2011;14:90–5.

    Article  PubMed  Google Scholar 

  78. Wong TZ, Lacy JL, Petry NA, Hawk TC, Sporn TA, Dewhirst MW, et al. PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. AJR Am J Roentgenol. 2008;190:427–32.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49 Suppl 2:129S–48S.

    Article  CAS  PubMed  Google Scholar 

  80. Hueting R, Kersemans V, Cornelissen B, Tredwell M, Hussien K, Christlieb M, et al. A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo. J Nucl Med. 2014;55:128–34.

    Article  CAS  PubMed  Google Scholar 

  81. Burgman P, O’Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32:623–30.

    Article  CAS  PubMed  Google Scholar 

  82. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989–98.

    CAS  PubMed  Google Scholar 

  83. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655–61.

    CAS  PubMed  Google Scholar 

  84. Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, et al. Application of 62Cu-diacetyl-bis(N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1alpha expression in patients with glioma. AJNR Am J Neuroradiol. 2013;34:92–9.

    Article  CAS  PubMed  Google Scholar 

  85. O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, PO2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493–502.

    Article  PubMed  Google Scholar 

  86. Matsumoto K, Szajek L, Krishna MC, Cook JA, Seidel J, Grimes K, et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]fluoromisonidazole positron emission tomography. Int J Oncol. 2007;30:873–81.

    CAS  PubMed  Google Scholar 

  87. Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323–8.

    Article  CAS  PubMed  Google Scholar 

  88. Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med. 2009;50:1948–53.

    Article  PubMed  Google Scholar 

  89. Oh M, Tanaka T, Kobayashi M, Furukawa T, Mori T, Kudo T, et al. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol. 2009;36:419–26.

    Article  CAS  PubMed  Google Scholar 

  90. Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008;35:713–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  91. Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, et al. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. Nucl Med Biol. 2003;30:529–34.

    Article  CAS  PubMed  Google Scholar 

  92. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–50.

    Article  CAS  PubMed  Google Scholar 

  93. Zhang T, Das SK, Fels DR, Hansen KS, Wong TZ, Dewhirst MW, et al. PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. AJR Am J Roentgenol. 2013;201:W698–706.

    Article  PubMed Central  PubMed  Google Scholar 

  94. Handley MG, Medina RA, Mariotti E, Kenny GD, Shaw KP, Yan R, et al. Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM. J Nucl Med. 2014;55:488–94.

    Article  CAS  PubMed  Google Scholar 

  95. Bowen SR, van der Kogel AJ, Nordsmark M, Bentzen SM, Jeraj R. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol. 2011;38:771–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  96. Toma-Dasu I, Dasu A, Brahme A. Quantifying tumour hypoxia by PET imaging – a theoretical analysis. Adv Exp Med Biol. 2009;645:267–72.

    Article  PubMed  Google Scholar 

  97. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with (18)F-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83:406–10.

    Article  CAS  PubMed  Google Scholar 

  98. Askoxylakis V, Dinkel J, Eichinger M, Stieltjes B, Sommer G, Strauss LG, et al. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial. Radiat Oncol. 2012;7:157.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Funding

This work received financial support from the Department of Health via the National Institute of Health Research Biomedical Research Centre award to Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust; and from the Comprehensive Cancer Imaging Centre, funded by the Cancer Research UK and Engineering and Physical Sciences Research Council in association with the Medical Research Council and Department of Health. Connie Yip receives funding support from the National Medical Research Council, Singapore.

Conflicts of interest

None.

Research involving human participants and/or animals

Not applicable.

Informed consent

Not applicable.

Author information

Authors and Affiliations

  1. Department of Cancer Imaging, Division of Imaging Sciences & Biomedical Engineering, King’s College London, St Thomas’ Hospital, London, UK

    Connie Yip, Vicky Goh, David B. Landau & Gary J. R. Cook

  2. Department of Radiation Oncology, National Cancer Centre, Singapore, Singapore

    Connie Yip

  3. Department of Imaging Chemistry & Biology, Division of Imaging Sciences & Biomedical Engineering, King’s College London, St Thomas’ Hospital, London, UK

    Philip J. Blower

  4. Department of Radiology, Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London, UK

    Vicky Goh

  5. Department of Clinical Oncology, Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London, UK

    David B. Landau

  6. Clinical PET Imaging Centre, Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London, UK

    Gary J. R. Cook

  7. Imaging 2, St Thomas’ Hospital, Level 1, Lambeth Wing, Lambeth Palace Road, London, SE1 7EH, UK

    Connie Yip

Authors
  1. Connie Yip
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip J. Blower
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vicky Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David B. Landau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gary J. R. Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Connie Yip.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yip, C., Blower, P.J., Goh, V. et al. Molecular imaging of hypoxia in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 42, 956–976 (2015). https://doi.org/10.1007/s00259-015-3009-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-015-3009-6

Keywords

Search

Navigation